Company profile
ADC Therapeutics SA
NYSE:ADCTBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CAMIDANLUMAB TESIRINE | phase1 | — | 2 | terminated |
| LONCASTUXIMAB TESIRINE | phase1 | — | 2 | completed, terminated |
| MIPASETAMAB UZOPTIRINE | phase1 | — | 2 | terminated |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (19)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05144009 | phase2 | terminated | 2022-06-21 | 2024-01-22 | ADC Therapeutics S.A. | A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) |
| NCT05389462 | phase1 | terminated | 2022-07-13 | 2025-04-17 | ADC Therapeutics S.A. | A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors |
| NCT05660395 | phase1 | terminated | 2023-07-28 | 2026-06-25 | ADC Therapeutics S.A. | A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) |
| NCT04970901 | phase1 | active_not_recruiting | 2022-06-17 | 2027-03-31 | ADC Therapeutics S.A. | A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) |
| NCT04972981 | phase1 | completed | 2021-09-09 | 2024-09-13 | ADC Therapeutics S.A. | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761196 | BLA | ADC Therapeutics SA | ||||
Loading… | ||||||